|1.||Chen, Yili: 1 article (11/2014)|
|2.||Chen, Shenglong: 1 article (11/2014)|
|3.||Wu, Lingling: 1 article (11/2014)|
|4.||Dong, Yugang: 1 article (11/2014)|
|5.||He, Jiangui: 1 article (11/2014)|
|6.||Huang, Huiling: 1 article (11/2014)|
|7.||Yao, Fengjuan: 1 article (11/2014)|
|8.||Miyoshi, Michio: 1 article (09/2006)|
|9.||Kitagawa, Yoshinori: 1 article (09/2006)|
|10.||Imoto, Toshiaki: 1 article (09/2006)|
|1.||Body Weight (Weight, Body)
10/01/1994 - "In protocol 1, HS-142-1 administration (by intravenous bolus of 20 mg.kg-1.body weight in all protocols) was not associated with significant changes in mean arterial pressure, heart rate, cardiac output or total peripheral resistance in the two groups of animals. "
05/01/1995 - "The increase in GFR and RPF in diabetic rats was significantly reduced, in a dose-dependent manner, by a single intravenous injection of HS-142-1; the maximal effect was apparent at a dose of 10 mg per kg of body weight. "
08/01/1998 - "Control (n=5) and study dogs (HS-142-1, n=9) underwent AVO with normal saline equal to 10% of body weight over 1 h. "
03/01/1999 - "The specific antagonist HS-142-1 was used to block the effects of NP in a model of high-output heart failure induced by an aortocaval shunt. "
05/01/1994 - "To elucidate the extent of the compensatory role of endogenous atrial natriuretic peptide (ANP) in severe congestive heart failure (CHF), we examined the changes in hemodynamics and neuroendocrine and renal functions after incremental administration of an ANP antagonist, HS-142-1 (HS), in dogs with CHF. "
05/01/1996 - "We administered HS-142-1 (HS), a specific antagonist of the guanylate cyclase-coupled ANP receptor, to conscious dogs with severe congestive heart failure (CHF) produced by rapid right ventricular pacing (n = 5, for 22 days) at doses of 0.3, 1.0, and 3.0 mg/kg at 30-minutes intervals. "
07/01/1994 - "To investigate the role of endogenous atrial natriuretic peptide (ANP) in rats with heart failure (HF), we administered HS-142-1 (HS; 3 mg/kg body wt iv), a novel nonpeptide ANP-receptor antagonist, to rats with surgically induced myocardial infarction and sham-operated rats. "
11/01/2014 - "We found that HS-142-1 increased Ang II-stimulated cardiomyocyte hypertrophy and Smad activation. "
11/01/2014 - "The effects of blockade of endogenous BNP by its receptor antagonist, HS-142-1, on cell hypertrophy were investigated. "
01/01/2000 - "The effects of the blockade of endogenous ANP by its receptor antagonist, HS-142-1, on cell hypertrophy were investigated with the use of cultured neonatal rat ventricular myocytes. "
11/01/2014 - "In addition, the increase of cardiomyocyte hypertrophy and the activation of Smad caused by HS-142-1 were not altered by the ERK inhibitor, PD98059, but were decreased by the p38 MAPK inhibitor, SB203580. "
01/01/2000 - "In addition, the expression levels of skeletal alpha-actin, beta-myosin heavy chain, and ANP genes, markers of hypertrophy, were partially elevated by treatment with HS-142-1 (100 microg/mL) under nonstimulated or PE-stimulated conditions. "
|2.||tranilast (N 5')
|5.||Atrial Natriuretic Factor (ANF)
|6.||Guanylate Cyclase (Guanylyl Cyclase)
|7.||Peptide Receptors (Peptide Receptor)
|8.||salicylhydroxamic acid (SHAM)
|9.||p38 Mitogen-Activated Protein Kinases